Varex to Highlight Advanced Imaging Components at Medica in Dusseldorf
Varex Imaging Corporation (Nasdaq: VREX) today announced it will showcase its digital detectors, X-ray imaging tubes, connect and control devices and software solutions at Medica 2019. Medica is attended by leaders in the fields of business and research, and international experts and decision-makers from the medical sector covering the entire spectrum of innovations for outpatient and clinical care.
Varex will also promote its ‘Local for Local’ campaign at Medica 2019 and introduce the company’s Service Solutions Group, which has been developed to provide local service to our customers with increased local X-ray tube and digital detector manufacturing and the aim of being global partners for local business.
“Our aim is to bring innovative X-ray imaging components to imaging systems manufacturers and we want to make that as easy as possible for our customers. By establishing local commercial relationships, delivering local service and support, and sourcing from local suppliers, we can be a global company and offer enhanced service capability that is local, hands-on, responsive, and easy to reach,” said Sunny Sanyal, Chief Executive Officer of Varex Imaging Corporation.
At Medica 2019, Varex will be highlighting its service and support and European customer experience by:
- enabling on-time delivery for common X-ray tube types in the radiological range of key brands
- providing technical support, evaluations and repairs of Varex digital detector flat panels/X-ray tubes at the company’s service centre in Willich, Germany
- giving access to local expert technical support for CT software, Nexus trainings and inquiries about X-ray detectors and tubes
Varex will be displaying a selection of their extensive portfolio of real-time digital X-ray imaging flat panel detectors (FPDs) at Medica 2019. Varex FPDs are developed using a variety of imaging technologies – amorphous silicon, CMOS and IGZO, which provide different benefits ideally suited to specific medical applications. For Surgery, Varex is showcasing 2020DXV/2121DXV and 3030DXV which are cost-efficient, high performance panels for Image Intensifier replacement. The company is also introducing the Varex Z platform which offers a new performance level with higher resolution and improved low dose performance over Amorphous Silicon, but without the cost burden of CMOS. Varex Z platform is based on IGZO technology and is very suitable for fluoroscopy applications with their bright scintillators, new electronics and fast interfaces. For Radiography, Varex will be showcasing its complete range of high value (2530W, 4336Wv4, 4343W) and high definition (XRpad2 3025, XRpad2 4336, XRpad2 4343) wireless panels. The Varex team of imaging experts will be on hand at Medica 2019 to advise customers on technology and packaged component solutions that are most suitable for their application; be it Radiography, Mammography, Fluoroscopy or Computed Tomography (CT). Varex Imaging will be providing Solutions in Sight™ at Medica 2019.
About Varex
At Varex, we aren’t just a supplier to our customers. We aim to be an extension of their teams; a partner in their success; a solution to their problem. Our goal is to enable our customers to become world-class system suppliers by strengthening their competitiveness and enabling them to bring products to market faster. Our rich history spans 65+ years of dedication to the imaging industry. Our knowledge, our people, and our innovation make us who we are. At Varex, we are Solutions in Sight™.
For more information about Varex visit: www.vareximaging.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191114005171/en/
Contact information
Kirstie Mogilner
Marketing Manager
+44 (0) 7909449409
kirstie.mogilner@vareximaging.com
Howard Goldman
Director of Investor & Public Relations
+1 (801) 978-5274
howard.goldman@vareximaging.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom